Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Ivosidenib

Stage Phase 1

Sponsor Servier

Route oral

Modality small molecule

Class mutant IDH1 inhibitor

Target IDH1 R132 (mutant)

Sources

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.19.03327

Mellinghoff IK et al. Ivosidenib in IDH1-mutated advanced glioma. J Clin Oncol 2020;38:3398-3406 (NCT02073994; abstract)

Brief source I11

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02073994

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Ivosidenib Phase 1 (glioma)

Registry NCT02073994

Phase Phase 1

Status Completed

Enrollment 174

Start 2014-03-01

Primary completion 2024-01-04

Study completion 2024-01-04

Ivosidenib, non-enhancing glioma

Dose Phase 1 doses

Regimen once daily

Population recurrent non-enhancing IDH1-mutant glioma

Estimand Single arm

median PFS: 13.6 months, 95% CI 9.2 to 33.2